Latest Breaking News On - சிஸ்டிக் ஃபைப்ரோஸிஸ் அடித்தளம் - Page 25 : vimarsana.com

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate . LongeveronFebruary 18, 2021 GMT MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors. Douglas Losordo, MD Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bio

United statesMiller schoolNew yorkUniversity of miamiDouglas losordoCathy rossErin borgerHead of researchOcwen financial corporationPublic offerings of commonwealth associatesSenior credit analyst for chase manhattan bankUniversity of vermont college medicineFinancial industry regulatory authorityFinancial services incCystic fibrosis foundationNorthwestern university feinberg school of medicine